Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term momentum without new products.
Zacks Investment Research on MSN5h
Here's Why Moderna Stock Soared 16% on WednesdayShares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on the open market. It also secured a legal victory in a patent dispute against Pfizer PFE and BioNTech BNTX.
Pfizer, Moderna and COVID-19
Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market. MRNA’s Court Victory A German court ruled that BioNTech (BNTX) and Pfizer (PFE) have to pay Moderna damages because they infringed on Moderna’s mRNA patents.
After finding support at $30, Moderna (MRNA) added nearly $5.00 to close at $35.21. The firm participated in TD Cowen’s annual healthcare conference. Moderna said it wants to expand its vaccine to have the broadest label.
Zacks.com on MSN10d
Vaccine Stocks Rise as Chinese Scientists Discover a New CoronavirusStocks of MRNA, PFE, NVAX and BNTX rose in anticipation that a new virus in China could trigger another pandemic.
Investopedia on MSN12d
Moderna and Other Vaccine Stocks Climb Amid Concerns About Coronavirus Study in ChinaConcerns about coronavirus news out of China may have moved some vaccine-maker and travel stocks Friday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback